PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pharmacol Ther. Author manuscript; available in PMC 2013 October 1.
Published in final edited form as:
PMCID: PMC3432694
NIHMSID: NIHMS395601

Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities

Abstract

Low-density lipoprotein receptor-related protein-1 (LRP1) is the main cell surface receptor involved in brain and systemic clearance of the Alzheimer's disease (AD) toxin amyloid-beta (Aβ). In plasma, a soluble form of LRP1 (sLRP1) is the major transport protein for peripheral Aβ. LRP1 in brain endothelium and mural cells mediates Aβ efflux from brain by providing a transport mechanism for A across the blood-brain barrier (BBB). sLRP1 maintains a plasma ‘sink’ activity for Aβ through binding of peripheral Aβ which in turn inhibits re-entry of free plasma Aβ into the brain. LRP1 in the liver mediates systemic clearance of Aβ. In AD, LRP1 expression at the BBB is reduced and Aβ binding to circulating sLRP1 is compromised by oxidation. Cell surface LRP1 and circulating sLRP1 represent druggable targets which can be therapeutically modified to restore the physiological mechanisms of brain Aβ homeostasis. In this review, we discuss how increasing LRP1 expression at the BBB and liver with lifestyle changes, statins, plant-based active principles and/or gene therapy on one hand, and how replacing dysfunctional plasma sLRP1 on the other regulate Aβ clearance from brain ultimately controlling the onset and/or progression of AD.

Keywords: Alzheimer's disease, Amyloid β-peptide, LRP1, soluble LRP1 (sLRP1), sLRP1 fragments

1. Introduction

The low-density lipoprotein receptor (LDLR)-related protein 1 (LRP1/CD91/α2-macroglobulin receptor), a member of the LDL receptor family, is a multifunctional scavenger, cargo transporter and signaling receptor (Dieckmann et al., 2010; Boucher & Herz, 2011). The gene encoding LRP1 is located on chromosome 12q13-q14 (Herz et al., 1988). LRP1 is ubiquitously expressed in many cell types, including brain endothelium, neurons, smooth muscle cells, astrocytes, macrophages, fibroblasts and hepatocytes (Moestrup et al., 1992). There are two forms of LRP1; cell surface bound (LRP1) and a truncated soluble form (sLRP1). sLRP1 is normally present in plasma (Quinn et al., 1997; Grimsley et al., 1999; Sagare et al., 2007; Sagare et al., 2011a), and under physiological conditions is found only in trace amounts in the cerebrospinal fluid (CSF) in humans (Qiu et al., 2001; Liu et al., 2009). LRP1 and sLRP interact with a diverse array of ligands (Lillis et al., 2008; Zlokovic et al., 2010; Boucher & Herz, 2011).

LRP1 is one of the largest receptors (600 kDa) in the LDL receptor family (Herz & Strickland, 2001; Dieckmann et al., 2010). It is synthesized as a single polypeptide chain, cleaved by the endopeptidase furin in the trans-Golgi compartment. The resulting extracellular heavy α-chain (515 kDa) remains non-covalently coupled to the extracellular region of the transmembrane and cytoplasmic light β-chain (85 kDa) (Fig. 1). LRP1 expression is controlled at both transcriptional and translational levels (Tamaki et al., 2007; Ceschin et al., 2009; Selvais et al., 2011). Cell surface levels of LRP1 are controlled by proteolytic shedding of its ectodomain (Quinn et al., 1999; May et al., 2002; Von Arnim et al., 2005; Polavarapu et al., 2007; Liu et al., 2009; Selvais et al., 2011).

Fig. 1
Schematic diagram showing the structure of cell surface bound LRP1 and soluble LRP1 (sLRP1). LRP1 ligand binding domains (green) are separated by epidermal growth factor (EGF)-precursor homology domain (blue). The single transmembrane domain (yellow) ...

LRP1, like all LDL receptors, is composed of a modular structural organization that includes cysteine-rich complement-type repeats (CRs), epidermal growth factor (EGF) precursor repeats and β-propeller (YWTD) domains (Lillis et al., 2008). The EGF precursor consists of two cysteine-rich EGF repeats, a YWTD repeat and another EGF-like repeat (Lillis et al., 2008). There are four ligand-binding domains in the extracellular region (clusters I-IV), consisting of 2, 8, 10 and 11 CRs, respectively (Obermoeller-McCormick et al., 2001; Meijer et al., 2007). Clusters II and IV are the major ligand binding regions interacting with approximately fifty structurally diverse ligands (Table 1) including: apolipoprotein E (apoE), α2-macroglobulin (α2M), tissue plasminogen activator (tPA), proteinase-inhibitors, blood coagulation factors (e.g., factor VIII), receptor-associated protein (RAP) (Hussain et al., 1999; Neels et al., 1999; Herz 2001; Herz & Strickland, 2001; Croy et al., 2003; Lillis et al., 2008; Meijer et al., 2007; Herz et al., 2009; Boucher & Herz, 2011), Alzheimer's amyloid-Aβ (Aβ) (Deane et al., 2004a; Sagare et al., 2007), prion protein (Parkyn et al., 2008; Jen et al., 2010) and aprotinin (Demeule et al., 2008a; 2008b). Thus, LRP1 plays a major role in the transport and metabolism of macromolecules especially cholesterol associated with apoE-containing lipoproteins, and clearance of proteases, protease inhibitors, matrix proteins, viruses and toxins, such as Aβ and prion.

Table 1
Classification of the diverse ligands of LRP1

While LRP1 has been regarded mainly as a receptor which internalizes its ligands and directs them to the lysosomes for proteolytic degradation, it has been also reported that LRP1 transports several ligands transcellularly across the blood-brain barrier (BBB) including Aβ (Shibata et al., 2000; Deane et al., 2004a; Davis et al., 2004; Wu et al., 2005; Cirrito et al., 2005; Bell et al., 2007), RAP (Pan et al., 2004), tPA (Benchenane et al., 2005), lipid free and lipidated apoE2 and apoE3, apoE2 and apoE3 complexes with Aβ (Deane et al., 2008) and a family of Kunitz domain-derived peptides (Demeule et al., 2008a; 2008b; Bertrand et al., 2011). These findings suggest that LRP1 may play a key role in regulating the exchange of several ligands between the brain and the blood.

The cytoplasmic domain of LRP1 contains two NPxY, one YxxL motifs and two di-leucine motifs (Li et al., 2001) (Fig. 1). It has been suggested that the YxxL motif and distal di-leucine repeats may be associated with a rapid endocytotic rate of LRP1 (Li et al., 2001; Deane et al., 2004a; Deane et al., 2008). The cytoplasmic tail is phosphorylated on several serine, threonine or tyrosine residues (Bu et al., 1998; Li et al., 2001; van der Geer, 2002). It interacts with a number of adaptor proteins including Shc, Disabled-1, JIP1, PSD-95, CED-6/GULP and Fe65 (Table 2), involved in directing cellular trafficking and transmembrane signaling (Trommsdorff et al., 1998; Gotthardt et al., 2000; Herz et al., 2009; Boucher & Herz, 2011). The NPxY motifs serve as docking sites for the adaptor proteins, Shc, Disabled-1, JIP1, PSD-95, CED-6/GULP Snx17 and Fe65. Phosphorylation of the cytoplasmic domain regulates interaction of adaptor proteins to the NPxY motifs and endocytosis (Li et al., 2001). Thus, LRP1 has a dual role as a rapid cargo endocytotic cellular transporter and a transmembrane cell signaling receptor.

Table 2
Proteins that bind to the light chain of LRP1

2. LRP1 and amyloid-β burden in Alzheimer's disease

2.1. LRP1 and AD

While some genetic studies have suggested that LRP1 is linked to AD and cerebral amyloid angiopathy (CAA) (Kang et al., 1997; Lambert et al., 1998; Wavrant-DeVrieze et al., 1999; Christoforidis et al., 2005), others have shown weak or no such association (Beffert et al., 1999; Bertram et al., 2000; Pritchard et al., 2005; Harold et al., 2009; Lambert et al., 2009; Bertram et al., 2010; Chalmers et al., 2010; Natunen et al., 2012). Earlier studies have demonstrated that LRP1 and many of its ligands are deposited in senile plaques (Rebeck et al., 1995; Arelin et al., 2002). In addition to regulating Aβ clearance from brain (Shibata et al., 2000; Deane et al., 2004a), it has been shown that the LRP1 cytoplasmic C-terminal domain interacts with APP's (Aβ-precursor protein) cytoplasmic domain via FE65, an LRP1 adaptor protein, which in turn influences the APP processing and Aβ generation (Pietrzik et al., 2004; Waldron et al.,2008). It has also been demonstrated that LRP1 in neurons mediates Aβ cellular uptake and possibly retention in the brain via its ligands α2M and apoE (Narita et al., 1997; Qiu et al., 1999; DeMattos et al., 2004; Zerbinatti et al., 2004; Zerbinatti & Bu, 2005; Deane et al., 2008). However, the exact implications of these findings for the development of Aβ pathology and cognitive decline remain unclear.

2.2. Aβ efflux across the blood-brain barrier

Aβ concentration in brain interstitial fluid (ISF) is regulated by its rate of production from APP (Selkoe, 2001a; Cirrito et al., 2003) and clearance from brain (Mawuenyega et al., 2010) and across the BBB mainly via LRP1 (Shibata et al., 2000; Deane et al., 2004a). In addition, influx of circulating Aβ into certain brain regions expressing the receptor for advanced glycation end products (RAGE) in brain endothelium may contribute to Aβ levels in brain (Deane et al., 2003; Dries et al., 2012). Aβ clearance is modulated by apoE in an isoform-specific manner (Zlokovic, 1996; Martel et al., 1997; Tanzi et al., 2004; Moir & Tanzi, 2005; Deane et al., 2008) and apoJ (Zlokovic et al., 1996; Calero et al., 2000; Bell et al., 2007). The enzymatic degradation of Aβ may also contribute to its clearance from brain (Selkoe, 2001b; Saido & Leissring, 2012). In contrast to the capillaries in peripheral organs allowing free exchanges of many molecules between the blood and the ISF (Mann et al., 1985), the BBB is normally impermeable to small polar molecules, peptides and proteins (Zloković et al., 1985; Zlokovic & Apuzzo, 1997). Therefore, transport of Aβ across the BBB requires a specialized transport system. Aβ is transported from blood to brain across the BBB of several species that have been studied including guinea-pigs, mice, rats and primates (Zlokovic et al., 1993; Ghilardi et al., 1996; Martel et al., 1996; Poduslo et al., 1997; Mackic et al., 1998b; Mackic et al., 2002; Ujiie et al., 2003; Eisele et al., 2010).

Several studies have reported that LRP1 transports Aβ from brain to blood (Shibata et al., 2000; Banks et al., 2003; Deane et al., 2004a; Ito et al., 2006; Bell et al., 2007; Deane et al., 2008; Bell et al., 2009) and is the main brain Aβ clearance receptor (Table 3). In contrast, RAGE mediates transport of blood-borne Aβ into brain and is associated with oxidant stress and pro-inflammatory response (Mackic et al., 1998a; Deane et al., 2003; Deane et al., 2012). RAGE expression has been found to be increased in brain endothelial cells and vascular smooth muscle cells in animal models of aging as well as in AD patients (Yan et al., 1996; Deane et al., 2003; Donahue et al.,2006; Miller et al., 2008; Silverberg et al., 2010b), whereas LRP1 expression is decreased both at the BBB and in cerebral arterial vascular smooth muscle cells (VSMC) (Shibata et al., 2000; Bading et al., 2002; Deane et al., 2004a; Donahue et al.,2006; Herring et al., 2008; Bell et al., 2009; Silverberg et al., 2010a). These changes in Aβ key transport receptors, therefore, favor accumulation of brain Aβ during AD pathogenesis.

Table 3
LRP1 as a major Aβ clearance receptor

2.3 LRP1 and sLRP1 roles in Aβ homeostasis

Continuous removal of Aβ from brain, blood and the entire organism is essential for preventing its accumulation in the brain (Zlokovic et al., 2000; Zlokovic et al., 2010; Zlokovic, 2011). As illustrated in Fig. 2, LRP1 plays a key role in the three-step serial clearance mechanism mediating Aβ elimination from the brain under physiological conditions. Step 1. Binding of Aβ to LRP1 at the abluminal brain endothelial cell membrane initiates rapid Aβ clearance across the BBB into the blood in vivo (Shibata et al., 2000; Deane et al., 2004a; Cirrito et al., 2005; Ito et al., 2006; Sagare et al., 2007; Bell et al., 2007; Deane et al., 2008; Bell et al., 2009). Human Aβ injected into different brain regions in mice emerges intact in murine plasma confirming its elimination from the brain (Shiiki et al., 2004; Bell et al., 2007). Step 2. Circulating plasma sLRP1 binds to and sequesters free Aβ in plasma providing a key endogenous peripheral Aβ ‘sink’ promoting continuous removal of Aβ from brain (Sagare et al., 2007; Sehgal et al., 2012). In humans and mice, sLRP1 normally binds > 70% of circulating Aβ preventing free Aβ access to the brain (Sagare et al., 2007). In AD patients and AD transgenic mice, however, increased oxidation of sLRP1 decreases binding affinity for Aβ (Sagare et al., 2007; Sagare et al., 2011) resulting in elevations in free Aβ40 and Aβ42 in plasma which may then lead to increased transport into the brain via RAGE (Deane et al., 2003; Ujiie et al., 2003; Donahue et al., 2006; Miller et al., 2008; Deane et al., 2012). Step 3. LRP1 localized to hepatic cells binds to and systemically clears circulating Aβ (Tamaki et al., 2006). Reduced hepatic LRP1 levels are associated with decreased peripheral Aβ clearance in aged rats (Tamaki et al., 2006; Tamaki et al., 2007). In aged Squirrel monkeys, Aβ systemic clearance is also reduced and associated with increased Aβ levels in the brain (Mackic et al., 1998b; Mackic et al., 2002). In addition to the liver, sLRP1-Aβ complexes and free Aβ are eliminated through the kidneys (Sagare et al., 2007). Recently, the liver was also shown to be a major source of Aβ and can regulate brain Aβ levels (Sutcliffe et al., 2011; Sagare et al., 2011b).

Fig. 2
Schematic diagram illustrating the role of LRP1 and sLRP1 in a three-step process controlling clearance of brain Aβ. Step 1: Transcytosis of Aβ by LRP1 on the abluminal surface of brain endothelial cells, from brain to blood across the ...

Besides endothelial cells, LRP1 is also expressed in other cell types of the neurovascular unit including pericytes (Bell et al., 2012), VSMC (Bell et al., 2009) and astrocytes (Koistinaho et al., 2004). It has been suggested that LRP1 in VSMC (Bell et al., 2009) and astrocytes (Koistinaho et al., 2004) participates in Aβ clearance. Whether LRP1 in pericytes can clear Aβ in vivo is presently not known. However, the role of LRP1 in maintaining the integrity of the BBB has been recently demonstrated (Bell et al., 2012). Therefore, one would expect that drugs that can increase LRP1 expression at the BBB will also promote LRP1-mediated Aβ clearance by other cell types in brain and improve the BBB integrity, assuming that these drugs can penetrate the BBB and reach their cellular targets in brain expressing LRP1.

3. LRP1/sLRP1 as therapeutic targets in Alzheimer's disease

The development of therapies that target brain Aβ to slow the progression of AD continues to be challenging (Hardy, 2009; Rosenberg, 2011; McKhann, 2011). There is an urgent need to explore new therapeutic approaches and to test these in clinical trials before disease onset (Rosenberg, 2011). Restoration or enhancement of normal LRP1-driven Aβ control mechanisms may offer new opportunities to reduce and/or prevent Aβ accumulation and the associated cognitive decline. As suggested by LRP1's three-step homeostatic control of brain Aβ levels, potential points of intervention are: (1) restoration and/or enhancement of BBB LRP1 expression, (2) replacement of dysfunctional sLRP1, and (3) restoration and/or enhancement of hepatic LRP1 expression.

Approaches directed at increasing LRP1 activity at the BBB and liver and/or replacing sLRP1 peripheral binding of Aβ that we discuss below are all designed to promote Aβ clearance from brain, which conceptually is similar to Aβ clearance therapy mediated by anti-Aβ antibodies (Deane et al., 2009; Mucke et al., 2009). But, some antibodies cross the BBB and can activate microglia response contributing to amyloid clearance, which is not a feature of LRP1-based therapy. Whether this aspect of antibody action contributes to microhemorrhages observed with some anti-Aβ antibodies (Deane et al., 2009), in contrast to LRP1-based approaches which do not cause hemorrhages (Sagare et al., 2007), is not clear at present. One would also expect that γ- and β-secretase inhibitors, by reducing the Aβ load in brain, will act synergistically with LRP1-based strategies directed at increasing Aβ clearance. However, the interaction of LRP1-based therapy with β-secretase inhibitors might be more complex because β-secretase also cleaves sLRP1 (von Arnim et al., 2005), which on one hand would increase the BBB and cellular Aβ clearance by increasing LRP1 levels, while on the other hand might reduce Aβ peripheral sink by lowering soluble sLRP1

3.1. Targeting BBB LRP1

LRP1 expression at the BBB is reduced during normal aging and in AD (Kang et al. 2000; Shibata et al., 2000; Bading et al., 2002; Deane et al., 2004a; Donahue et al., 2006; Silverberg et al., 2010a). Therefore, normalization or enhancement of LRP1 levels at the BBB should increase the clearance of Aβ from brain and restore control of brain Aβ levels. Increased BBB LRP1 expression may be achieved by: (a) lifestyle changes (e.g., diet, exercise and enriched environment), (b) pharmacological agents (e.g., statins, plant-based active principles), and (c) gene therapy.

3.1.1. Lifestyle changes: Prevention

Cerebral oxidative stress is increased in AD (Smith et al., 1991; Montine et al., 2002; Lovell & Markesbery, 2007), and could render BBB LRP1 dysfunctional as a result of oxidation and/or reduced proteosomal degradation (Deane et al., 2004a). Therefore, enhancing the body's natural anti-oxidant defense mechanisms, with antioxidant nutrients, such as polyphenol-rich foods (Williams & Spencer, 2012; Hwang et al., 2012), vitamin A, C and E, could potentially protect LRP1 from oxidative damage, and thus reduce associated declines in Aβ clearance and cognitive function. In rodents, antioxidants supplemented in the diet including vitamins (Sung et al., 2004), grape seed extract (Liu et al., 2011), wine (Wang et al., 2006; Ho et al., 2009), pomegranate juice (Hartman et al., 2006), blackberries (Shukitt-Hale et al., 2009), wild blueberry extract (Papandreou et al., 2009), green tea (Chan et al., 2006; Assunção et al., 2011) or extra virgin olive oil (Farr et al., 2012) improved learning acquisition and memory retention. Some preliminary studies suggest that diet supplemented with polyphenols improves memory in older adults (Krikorian et al., 2010a; Krikorian et al., 2010b). A higher intake of vitamin C and E (Masaki et al., 2000; Engelhart et al., 2002; Zandi et al., 2004) and vitamin E (Morris et al., 2002) have been shown in some studies to be associated with a reduced risk of AD. However, other studies in different populations have failed to show this association (Sano et al., 1997; Luchsinger et al., 2003; Petersen et al., 2005; Galasko et al., 2012) and the collective results from clinical trials remain equivocal.

Physical activity bolsters cerebral angiogenesis in rodents (Isaacs et al., 1992; Swain et al., 2003; Pereira et al., 2007; Latimer et al., 2011) and human subjects (Pereira et al., 2007) and may delay cognitive decline by reducing cerebrovascular risk, including the contribution of small vessel disease to dementia (Ahlskog et al., 2011). In chronic conditions, such as AD, aberrant angiogenesis reduces vascular density thereby leading to reductions in both capillary perfusion and Aβ clearance contributing to neurodegeneration (Wu et al; 2005; Zlokovic et al., 2005). Physical activity and cognitive stimulation in the form of enriched environment consisting of various objects (tunnels, balls, soft materials and locomotive items, such as wooden ramp, ladders, stairs and running wheel) resulted in significant reduction in cerebral amyloid-β deposits in AD transgenic mice (Lazarov et al., 2005; Adlard et al., 2005; Ambree et al., 2006; Herring et al., 2008). Mice subjected to enriched environment for 4 weeks also showed up-regulation of pro-angiogenic genes, increased cerebral vessel density, along with decreased cerebral levels of RAGE and increased LRP1 levels which would favor a net clearance of Aβ from brain (Herring et al., 2008). Increased cerebrovascular density would lead to a larger surface area for transport of molecules across the BBB. Recent studies have shown beneficial effects of physical activity on cognition in older adults (Lautenschlager et al., 2008; Middleton et al., 2008; Baker et al., 2010; Ahlskog et al., 2011; Graff-Radford, 2011; Tseng et al., 2011).

3.1.2. Pharmacological approach: Statins and plant-based therapeutics

Cholesterol is an essential component of the cell membrane and an important precursor for both steroids and bile acids. Hypercholesterolemia is a major risk factor of vascular disease (Kannel et al., 1971). Some studies have indicated that elevated serum cholesterol levels might increase the risk of AD (Notkola et al., 1998; Kivipelto et al., 2001; Schneider & Simons, 2012). Systemic and central cholesterol levels maybe controlled independently since the BBB restricts the transport of apolipoprotein-containing cholesterol from blood to brain (Martel et al., 1997) and from brain to blood (Bell et al., 2007; Deane et al., 2008). Statins are cholesterol lowering drugs that reversibly inhibit the rate-limiting enzyme, hydroxymethylglutaryl-coenzyme A (HMGCoA) reductase, in cholesterol biosynthesis (Goldstein & Brown, 1990). There are several statins, including simvastatin, atorvastatin, fluvastatin, cerivastatin, pitavastatin, pravastatin and rosuvastatin, each of which has differences in physio-chemical properties (Illingworth et al., 2001). The lipophilic statins, such as simvastatin and atorvastatin, are more likely to enter the brain than the hydrophilic statins, such as pravastatin and rosuvastatin (Vuletic et al., 2006; Sierra et al., 2011).

Retrospective case studies have suggested that statins reduce the risk of AD (Jick et al., 2000; Wolozin et al., 2007), but prospective studies and clinical trials have produced inconsistent data (Di Paolo & Kim, 2011) with some showing reduced risk (Wolozin et al., 2000; Cramer et al., 2008; Sparks et al., 2008; Haag et al., 2009) and others showing no change (Rea et al., 2005; Zandi et al., 2005; McGuinness et al., 2009; Benito-Leon et al., 2010; Feldman et al., 2010). These conflicting data may be due to a number of factors, including the type of statin used, duration of the treatment, baseline cholesterol plasma levels, age at which the statin therapy was started and whether a given statin can enter the brain and influence central (e.g., CSF) cholesterol levels. Interestingly, there were no differences in the reduction in risk of AD produced by simvastatin (BBB permeable) and pravastatin (BBB impermeable) (Haag et al., 2009). In addition to lowering cholesterol, statins possess multiple cholesterol-independent beneficial effects (Evans et al., 2009). For example, they increase endothelial nitric oxide (NO) production and blood flow by upregulating NO-synthase (Laufs et al., 1998), increase tPA levels (Essig et al., 1998) and reduce levels of the potent vasoconstrictor endothelin-1 (Hernandez-Perera et al., 1998). Collectively, these changes could increase cerebral blood flow which could revitalize the brain and help mitigate neuronal dysfunction (Bell et al., 2009; Zlokovic, 2011).

Statins increase the expression of LDL receptors and LRP1 in organs such as the liver (Rudling et al., 1992; Moon et al., 2011a). However, there is little work on the role of statins on LRP1 expression at the BBB. Our earlier studies have shown that treatment of human brain endothelial cells with simvastatin or lovastatin increased expression of LRP1 (Deane et al., 2004b). In a transgenic mouse model of AD (APP23), treatment with fluvastatin orally for 4 weeks increased LRP1 expression levels at the BBB leading to increased Aβ clearance and reduced accumulation (Shinohara et al., 2010). While these are promising data further work is needed to study the role of statins on LRP1 expression at the BBB and brain in AD.

In a recent study, Probucol, a non-statin cholesterol-lowering drug was found to prevent cognitive impairment induced by Aβ peptide in mice (Santos et al., 2012). Probucol was originally synthesized as an antioxidant (Yamamoto, 2008) but later found to have cholesterol lowering properties (Buckley et al., 1989). It is of note that Probucol administration in aged rats for 30 days resulted in a significant increase in hippocampal LRP1 expression (Champagne et al., 2003).

Plant-based active principles have played a vital role in modern drug development. In a recent report, oral administration of an extract from the root of Withania somnifera was shown to enhance LRP1 expression in brain microvessels and liver and increase the levels of circulating sLRP1 in plasma resulting in reversal of AD pathology in APP/PS1 AD transgenic mice (Sehgal et al., 2012; Dries et al., 2012).

3.1.3. Gene therapy

While the BBB is also a major obstacle to the effective delivery of gene transfer vectors into the brain, restoration of age-dependent or disease-associated reductions in LRP1 expression at the BBB may be accomplished through specific targeting of cerebrovascular endothelial cells. Endothelial cells are the cellular constituents of the BBB and possess two opposing plasma membranes: one facing the vascular lumen and is exposed to blood and one facing brain parenchyma and is exposed to brain interstitial fluid. Therefore, when targeting cerebrovascular endothelial cells, gene transfer vectors do not need to cross the BBB given direct plasma exposure when administered systemically. Effective gene transfer can be achieved with either non-viral or viral systems. However, viral based systems are usually more effective in mediating cell entry and transfer of genes to the target cell and are in many instances preferred (Davidson et al., 2000). Adeno-associated virus (AAV) is frequently used as a vector for gene therapy for achieving long-term gene expression in both dividing and non-dividing cells (Grieger & Samulski, 2012). AAV also lacks pathogenicity as it is unable to autonomously replicate without a helper virus (Grieger & Samulski, 2012). The capsid amino acid sequence for AAV serotypes are different, except 1 and 6 (Daya & Berns, 2008), and may contribute to host cell specificity. Of the common serotypes, AAV-2 has been developed for transduction of brain endothelial cells by phage panning (Chen et al., 2009), and was used in neurological studies in mouse models of lysosomal storage disease (Fu et al., 2002; Chen et al., 2009) and Parkinson disease (Bankiewicz et al., 1998). Recently, AAV-9 with a lower prevalence of neutralizing antibodies in humans and more efficient gene transfer capacity in vivo has been developed for endothelial cell-directed gene transfer (Varadi et al., 2011).

Targeting the gene transfer vector to the BBB could be direct or indirect. In the direct approach, vector targeting is mediated by a small peptide that has been inserted into the viral capsid sequence to modify viral tropism, as used for endothelial cells (Stachler & Bartlett, 2006; White et al., 2004). This could be enhanced by identifying molecular signature epitopes in the cerebral endothelial cells of AD brains and presenting these epitopes on the capsid of AAV to enhance site-specific distribution after intravenous injections (Chen et al., 2009). In lysosomal storage disease, specific epitopes have been identified suggesting unique vascular signature imparted by the disease (Liu et al., 2005; Chen et al., 2009). The indirect targeting involves associating molecules that interact with both viral surface and the specific cell surface receptor such as antibodies (Bartlett et al., 2000) and biotin (Ponnazhagan et al., 2002). In summary, it may be possible to use AAV-2 carrying the cDNA of LRP1 or its smaller fragments to restore reduced LRP1 expression in brain vascular endothelial cells in AD.

3.2. sLRP1 replacement for Alzheimer's disease

In plasma, sLRP1 is the main carrier of plasma Aβ since it binds 70-90% of Aβ in normal individuals (Sagare et al., 2007). In AD patients, sLRP1 levels are reduced by about 30% and dysfunctional due to its oxidation (Sagare et al., 2007). Consequently, there is reduced Aβ binding to sLRP1 resulting in an increase of free Aβ levels in plasma (Sagare et al., 2007; Sagare et al., 2011a) which could re-enter brain via RAGE (Martel et al., 1996; Deane et al., 2004a, 2004b). In mild cognitive impairment (MCI), patients who progress to AD (MCI-AD) and AD patients have greater levels of oxidized sLRP1 and free Aβ in plasma. Furthermore, these elevations correlate with established biomarkers such as increased CSF tau/Aβ42 ratio and reduced MMSE scores (Sagare et al., 2011a). In a mouse model of AD (6 months of age), treatment with low levels (40 g/kg) of recombinant wild type ligand binding domain IV of LRP1 (LRPIV), a truncated form of endogenous LRP1 which consists of a single binding domain with high affinity for Aβ for 3 months reduced brain Aβ levels, improved cerebral blood flow (CBF) responses to brain stimulation and enhanced learning and memory without altering plasma levels of other LRP1 ligands such as apoE, tPA, and MMP9 (Sagare et al., 2007). Treatment with LRPIV did not affect levels of LDLR and LRP1 in brain, liver or kidneys, nor did it affect the levels of phosphorylated LRP1 in brain and liver (Sagare et al., 2007). LRPIV did not enter CSF (Sagare et al., 2007) and, therefore, it was efficacious systemically. These data demonstrated that recombinant LRPIV holds potential as a replacement therapy for AD and should be explored in other pre-clinical models. To further enhance specificity for binding Aβ in relative isolation of other plasma ligands, site-directed mutagenesis was performed with LRPIV (Zlokovic et al., 2009). A lead mutant LRPIV has been identified and selected as a result of its preferential binding to Aβ40 and Aβ42. More specifically, this LRP1 fragment binds Aβ42 with 3-fold greater affinity than the LRPIV used in the earlier studies, while binding other LRP1 ligands with reduced affinity (Sagare et al., 2007). This mutant LRPIV may, therefore, represent a more effective sLRP1 replacement therapy for MCI-AD and AD patients than endogenous sLRP1.

3.3. Targeting liver LRP1

One of the major functions of the liver is to regulate the levels of multiple diverse plasma proteins through controlling both biosynthesis and clearance (Charlton, 1996). LRP1 is highly expressed in hepatocytes serving as a cargo transporter of many macromolecules, including chylomicron remnants (Willnow et al., 1994; Mahley & Huang, 2007), α2 macroglobulin (Willnow et al., 1995; Poller et al., 1995), serine protease inhibitors (serpin)-enzyme complex (Kounnas et al., 1996; Maekawa & Pollefsen, 1996) and factor VIII (Lenting et al., 1999; Bovenschen et al., 2003). Interestingly, conditional deletion of LRP1 from liver reduced the plasma levels of HDL-containing cholesterol compared to wild-type mice (Basford et al., 2011). Recently, the liver was shown to be a major source of peripheral Aβ and that inhibition of peripheral Aβ production with Gleevec reduced plasma and brain Aβ levels (Sutcliffe et al., 2011; Sagare et al., 2011b). The liver is also a major organ for rapid peripheral clearance of Aβ (Tamaki et al., 2006) and LRPIV-Aβ complexes (Sagare et al., 2007). Hepatic LRP1 levels have been shown to be reduced in aging rats, and this is associated with decreased peripheral Aβ clearance (Tamaki et al., 2006; Tamaki et al., 2007). Increased Aβ level in brain is associated with reduced systemic Aβ clearance in aging Squirrel monkeys (Mackic et al., 1998b; 2002). It is also possible that the age-dependent reduction in liver LRP1 expression may contribute to systemic accumulation of macromolecules normally cleared by LRP1 that could lead to atherosclerotic lesions (Espirito Santo et al., 2004). Thus, restoring normal LRP1 levels in liver is essential for peripheral clearance of Aβ and the sink action for removal of brain Aβ. Potential therapies to increase LRP1 expression levels in liver include a) statins, b) insulin, and c) expression of recombinant LRP1 fragments such as LRPIV by gene therapy.

3.3.1. Statins

The liver is the major organ for the synthesis of peripheral apolipoprotein-associated cholesterol and, therefore, targeted by statins to reduce systemic cholesterol levels and consequently decreasing the risk of cardiovascular disease or stroke (Hiki et al., 2009). In the liver, statins not only decrease the synthesis of cholesterol but also increase the expression levels of LDLR, which increases the uptake and clearance of systemic apolipoprotein-associated cholesterol. However, studies on the role of statins on LRP1 expression in this organ are limited. In one study, rats treated orally with atorvastatin (20 mg/kg, daily) for 6 weeks starting at 20 weeks of age had increased levels of LRP1 and, as expected, LDLR in the liver (Moon et al., 2011a). Identifying statins that can increase the LRP1 expression levels at the BBB and in liver could provide rapid and effective clearance of brain Aβ Further work is needed to extend these studies using different statins, doses, duration of treatment, different starting ages of treatment, different models of AD and in different species.

3.3.2. Insulin

Epidemiological studies have suggested an association between insulin-resistant type II diabetes mellitus and AD (Matsuzaki et al., 2010). However, the mechanism for this is unclear. Since insulin is lower in type II diabetes, its role in regulating LRP1 in liver was explored. In rats, insulin treatment increased LRP1 levels in the liver by facilitating its translocation to the hepatic plasma membrane which enhanced LRP1-dependent Aβ clearance by the liver (Tamaki et al., 2007). If these findings could be confirmed in humans, then insulin treatment would potentially benefit a subgroup of AD patients.

3.3.3. Gene therapy

One of the goals would be to selectively enhance LRP1-dependent Aβ clearance by the liver but no other LRP1 ligands in plasma, so as to minimize the risk of potential adverse effects. Similar to the approach suggested for targeting cerebrovascular cells in the BBB, including gene transfer vector to express mutant LRPIV (Zlokovic et al., 2009) may selectively increase the clearance of peripheral Aβ via the liver without significant changes in plasma levels of other LRP1 ligands. The most promising gene transfer vector system for the liver is the AAV vectors, which have been successfully used for many liver disorders including hypercholesterolemia (Lebherz et al., 2004; Van Craeyveld et al., 2011). Using a vector dose of 1012 genome copies (gc) carrying the human LDLR cDNA and the liver specific promoter thyroxin binding globulin (TBG), the transduction efficiency was 25-fold greater for AAV-8 compared to AAV-2 in LDLR-/- mice (Lebherz et al., 2004). AAV-8 achieved a stable transduction, high levels of LDLR expression in liver, without toxic effects and normalized plasma lipid profile. AAV-8 is highly effective in liver transduction in several species including mice, dogs and non-human primates, and the expression of green fluorescent protein is not affected by the type of promoters (Bell et al., 2011). At present, AAV-8 has the most favorable features for clinical applications of liver-directed gene transfer (Wang, 2011). It may be possible to use AAV-8 to carry the cDNA of a mutant LRPIV and a liver-restricted promoter to restore normal function of LRP1 in the liver of AD patients. While this approach appears feasible, it needs to be tested in mouse models of AD for its efficacy in controlling brain Aβ levels.

4. Conclusions

We have reviewed the evidence suggesting that LRP1 has a major role in regulating the clearance of Alzheimer's Aβ from brain. Specifically, we have discussed LRP1-based potential therapeutic interventions at three steps in restoring the normal controlling mechanisms regulating brain Aβ levels. The multimodal regulatory roles of cell surface LRP1 at the BBB, circulating soluble LRP1 and LRP1 in peripheral organs such as the liver could be a major but still underexplored therapeutic target in AD.

Although most AD patients are affected by one or two vascular risk factors and/or develop vascular changes in brain (i.e., > 65% of cases over the age of 60 and > 85% of cases over 80) (Wu et al., 2005; Bell et al., 2009; Zlokovic, 2011), it remains elusive whether MCI patients who later develop vascular dementia without amyloid deposition can also develop lower activity in the LRP1 system (Sagare et al., 2011). Future studies should address this important issue. It would be interesting to determine the impact of the LRP1 system on non-Aβ related vascular pathway of AD pathogenesis. For instance, recent findings indicated that pericytes are critical for maintaining the BBB integrity (Bell et al., 2010), and that the inability of astrocyte-secreted apoE (i.e., apoE4) to interact with LRP1 on pericytes may lead to BBB breakdown and microvascular degeneration followed by secondary neuronal degeneration (Bell et al., 2012). This latter study suggested that lower expression of LRP1 in vascular cells may promote vascular dysfunction and secondary neuronal degeneration independently of Aβ clearance. More studies are needed, however, to clarify the exact role of LRP1 in vascular dementia

Some studies have shown that BBB is leakier in AD patients than in age-matched controls (Zipser et al., 2007; Farrall & Wardlaw, 2009). Exactly how this influences the LRP1 clearance system in brain is not clear at present. It is conceivable that focal BBB disruptions will allow more Aβ to enter the brain from the periphery which might add an additional burden to the LRP1 clearance mechanism at the BBB.

Pharmacological and/or gene therapy strategies have been shown to increase the levels of LRP1 at the BBB and may hold the potential to prevent and/or reduce Aβ accumulation during AD pathogenesis. Replacement therapy for the native oxidized and dysfunctional circulating sLRP1 with recombinant LRP1 clusters may help maintain the peripheral Aβ ‘sink’ activity at an early stage of the disease in patients with MCI by reducing the influx of circulating Aβ into the brain which may slow down disease progression. Oxidized sLRP1 in plasma, which does not bind peripheral Aβ, is also an important early biomarker in MCI individuals converting into AD as well as in AD patients. Finally, approaches to increase LRP1 expression in peripheral organs such as the liver pharmacologically or by gene therapy might help promote systemic Aβ elimination, which has been shown to improve peripheral Aβ-‘sink’ activity by reducing sLRP1-Aβ and free Aβ levels in plasma and promoting Aβ clearance from the brain.

As a note of caution, we would like to stress that the development of LRP1-based therapies for AD requires careful toxicity and safety monitoring of unwanted potential side effects given that LRP1 participates in multiple control systems in the body, i.e., from the cellular transport and metabolism of cholesterol to anticoagulation and inflammation. However, our preliminary findings suggest that LRP1-based therapeutics such as the recombinant LRP1 clusters (Zlokovic et al., 2009) can be tailored by genetic engineering to be more specifically directed at Aβ with minimal effects on other systems in the body. These new LRP1 variants produced by site-directed LRP1 mutagenesis may have the potential either as recombinant proteins adapted for systemic administration and/or as Aβ-selective LRP1 gene constructs adapted for tissue-specific expression in the brain, liver and/or other peripheral organs.

Acknowledgements

Findings were supported by R37 AG023084, R37 NS34467 and HL63290, the ALS Association (grant 1859) and the Zilkha family to B.V. Zlokovic and AG29481 to R. Deane. The authors thank Ethan Winkler for critical reading.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest statement

BVZ is the scientific founder of Socratech LLC, a start-up biotechnology company with a mission to develop new therapeutic approaches for stroke and Alzheimer's disease. APS and RD have no conflicts of interest to disclose.

References

  • Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:4217–4221. [PubMed]
  • Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc. 2011;86:876–884. [PMC free article] [PubMed]
  • Ambree O, Leimer U, Herring A, Gortz N, Sachser N, Heneka MT, Paulus W, Keyvani K. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol. 2006;169:544–552. [PubMed]
  • Arelin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, Hyman BT. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res. 2002;104:38–46. [PubMed]
  • Assuncao M, Santos-Marques MJ, Carvalho F, Lukoyanov NV, Andrade JP. Chronic green tea consumption prevents age-related changes in rat hippocampal formation. Neurobiol Aging. 2011;32:707–717. [PubMed]
  • Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, Ghiso J, Frangione B, Zlokovic BV. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target. 2002;10:359–368. [PubMed]
  • Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol. 2010;67:71–79. [PMC free article] [PubMed]
  • Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006;14:564–570. [PubMed]
  • Banks WA, Robinson SM, Verma S, Morley JE. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience. 2003;121:487–492. [PMC free article] [PubMed]
  • Barnes H, Larsen B, Tyers M, van Der Geer P. Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells. J Biol Chem. 2001;276:19119–19125. [PubMed]
  • Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. 2000;74:2777–2785. [PMC free article] [PubMed]
  • Basford JE, Wancata L, Hofmann SM, Silva RA, Davidson WS, Howles PN, Hui DY. Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice. J Biol Chem. 2011;286:13079–13087. [PubMed]
  • Beffert U, Arguin C, Poirier J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. Neurosci Lett. 1999;259:29–32. [PubMed]
  • Bell P, Wang L, Gao G, Haskins ME, Tarantal AF, McCarter RJ, Zhu Y, Yu H, Wilson JM. Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. Mol Genet Metab. 2011;104:395–403. [PMC free article] [PubMed]
  • Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143–153. [PMC free article] [PubMed]
  • Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–918. [PMC free article] [PubMed]
  • Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512–516. [PubMed]
  • Benchenane K, Berezowski V, Ali C, Fernandez-Monreal M, Lopez-Atalaya JP, Brillault J, Chuquet J, Nouvelot A, MacKenzie ET, Bu G, Cecchelli R, Touzani O, Vivien D. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation. 2005;111:2241–2249. [PubMed]
  • Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21:95–102. [PubMed]
  • Bertram L, Blacker D, Crystal A, Mullin K, Keeney D, Jones J, Basu S, Yhu S, Guenette S, McInnis M, Go R, Tanzi R. Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies. Exp Gerontol. 2000;35:1353–1361. [PubMed]
  • Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270–281. [PubMed]
  • Bertrand Y, Currie JC, Poirier J, Demeule M, Abulrob A, Fatehi D, Stanimirovic D, Sartelet H, Castaigne JP, Beliveau R. Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer. 2011;105:1697–1707. [PMC free article] [PubMed]
  • Boucher P, Herz J. Signaling through LRP1: Protection from atherosclerosis and beyond. Biochem Pharmacol. 2011;81:1–5. [PMC free article] [PubMed]
  • Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, van Vlijmen BJ. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood. 2003;101:3933–3939. [PubMed]
  • Bu G, Sun Y, Schwartz AL, Holtzman DM. Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. J Biol Chem. 1998;273:13359–13365. [PubMed]
  • Buckley MM, Goa KL, Price AH, Brogden RN. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989;37:761–800. [PubMed]
  • Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000;50:305–315. [PubMed]
  • Ceschin DG, Sanchez MC, Chiabrando GA. Insulin induces the low density lipoprotein receptor-related protein 1 (LRP1) degradation by the proteasomal system in J774 macrophage-derived cells. J Cell Biochem. 2009;106:372–380. [PubMed]
  • Chalmers KA, Barker R, Passmore PA, Panza F, Seripa D, Solfrizzi V, Love S, Prince JA, Kehoe PG. LRP-1 variation is not associated with risk of Alzheimer's disease. Int J Mol Epidemiol Genet. 2010;1:104–113. [PMC free article] [PubMed]
  • Champagne D, Pearson D, Dea D, Rochford J, Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience. 2003;121:99–110. [PubMed]
  • Chan YC, Hosoda K, Tsai CJ, Yamamoto S, Wang MF. Favorable effects of tea on reducing the cognitive deficits and brain morphological changes in senescence-accelerated mice. J Nutr Sci Vitaminol. 2006;52:266–273. [PubMed]
  • Charlton MR. Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab. 1996;10:617–635. [PubMed]
  • Chen YH, Chang M, Davidson BL. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med. 2009;15:1215–1218. [PMC free article] [PubMed]
  • Christoforidis M, Schober R, Krohn K. Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2005;31:11–19. [PubMed]
  • Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285–3290. [PMC free article] [PubMed]
  • Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844–8853. [PubMed]
  • Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344–350. [PMC free article] [PubMed]
  • Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A. 2000a;97:3428–3432. [PubMed]
  • Davidson JM, Krieg T, Eming SA. Particle-mediated gene therapy of wounds. Wound Repair Regen. 2000b;8:452–459. [PubMed]
  • Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem. 2004;279:20296–20306. [PubMed]
  • Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583–593. [PMC free article] [PubMed]
  • Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907–913. [PubMed]
  • Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–4013. [PMC free article] [PubMed]
  • Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004a;43:333–344. [PubMed]
  • Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004b;35:2628–2631. [PubMed]
  • Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurol Disord Drug Targets. 2009;8:16–30. [PMC free article] [PubMed]
  • Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Meenakshisundaram T, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV. Multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122:1377–1392. [PMC free article] [PubMed]
  • DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193–202. [PubMed]
  • Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008a;106:1534–1544. [PubMed]
  • Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Beliveau R. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008b;324:1064–1072. [PubMed]
  • Derocq D, Prebois C, Beaujouin M, Laurent-Matha V, Pattingre S, Smith GK, Liaudet-Coopman E. Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis. Oncogene. 2011 [PMC free article] [PubMed]
  • Dieckmann M, Dietrich MF, Herz J. Lipoprotein receptors--an evolutionarily ancient multifunctional receptor family. Biol Chem. 2010;391:1341–1363. [PMC free article] [PubMed]
  • Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. 2006;112:405–415. [PubMed]
  • Dries DR, Yu G, Herz J. Extracting beta-amyloid from Alzheimer's disease. Proc Natl Acad Sci U S A. 2012;109:3199–3200. [PubMed]
  • Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980–982. [PMC free article] [PubMed]
  • Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002;287:3223–3229. [PubMed]
  • Espirito Santo SM, Pires NM, Boesten LS, Gerritsen G, Bovenschen N, van Dijk KW, Jukema JW, Princen HM, Bensadoun A, Li WP, Herz J, Havekes LM, van Vlijmen BJ. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. Blood. 2004;103:3777–3782. [PubMed]
  • Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res. 1998;83:683–690. [PubMed]
  • Evans NS, Green D. ASH evidence-based guidelines: statins in the prevention of venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2009:273–274. [PubMed]
  • Farr SA, Price TO, Dominquez LJ, Motisi A, Saiano F, Niehoff ML, Morley JE, Banks WA, Ercal N, Barbagallo M. Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alz Dis. 2012;28:81–92. [PubMed]
  • Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging. 2009;30:337–352. [PubMed]
  • Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956–964. [PubMed]
  • Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther. 2002;5:42–49. [PubMed]
  • Fujiyoshi M, Tachikawa M, Ohtsuki S, Ito S, Uchida Y, Akanuma SI, Kamiie J, Hashimoto T, Hosoya KI, Iwatsubo T, Terasaki T. Amyloid-beta peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem. 2011;118:407–415. [PubMed]
  • Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer's disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 doi:10.1001/archneurol.2012.85. [PMC free article] [PubMed]
  • Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, Mantyh PW. Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport. 1996;7:2607–2611. [PubMed]
  • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. [PubMed]
  • Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000;275:25616–25624. [PubMed]
  • Graff-Radford NR. Can aerobic exercise protect against dementia? Alzheimers Res Ther. 2011;3:6. [PMC free article] [PubMed]
  • Grimsley PG, Quinn KA, Chesterman CN, Owensby DA. Evolutionary conservation of circulating soluble low density lipoprotein receptor-related protein-like (“LRP-like”) molecules. Thromb Res. 1999;94:153–164. [PubMed]
  • Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13–17. [PubMed]
  • Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110:1129–1134. [PubMed]
  • Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088–1093. [PMC free article] [PubMed]
  • Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis. 2006;24:506–515. [PubMed]
  • Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–2719. [PMC free article] [PubMed]
  • Herring A, Yasin H, Ambree O, Sachser N, Paulus W, Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol. 2008;18:32–39. [PubMed]
  • Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 2001;29:571–581. [PubMed]
  • Herz J, Chen Y, Masiulis I, Zhou L. Expanding functions of lipoprotein receptors. J Lipid Res. 2009;50(Suppl):S287–292. [PubMed]
  • Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO Jl. 1988;7:4119–4127. [PubMed]
  • Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779–784. [PMC free article] [PubMed]
  • Hiki M, Shimada K, Ohmura H, Kiyanagi T, Kume A, Sumiyoshi K, Fukao K, Inoue N, Mokuno H, Miyazaki T, Daida H. Serum levels of remnant lipoprotein cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease. J Cardiol. 2009;53:108–116. [PubMed]
  • Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Dickstein DL, Pasinetti GM. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. J Alz Dis. 2009;16:59–72. [PMC free article] [PubMed]
  • Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, Wang YY, Wang Y, Li YQ, Long Y, Xia YZ. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology. 2009;56:1054–1059. [PubMed]
  • Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr. 1999;19:141–172. [PubMed]
  • Hwang SL, Shih PH, Yen GC. Neuroprotective effects of citrus flavonoids. J Agric Food Chem. 2012;60:877–885. [PubMed]
  • Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719–726. [PubMed]
  • Illingworth DR, Crouse JR, 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43–50. [PubMed]
  • Isaacs KR, Anderson BJ, Alcantara AA, Black JE, Greenough WT. Exercise and the brain: angiogenesis in the adult rat cerebellum after vigorous physical activity and motor skill learning. J Cereb Blood Flow Metab. 1992;12:110–119. [PubMed]
  • Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem. 2007;103:2482–2490. [PubMed]
  • Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res. 2006;56:246–252. [PubMed]
  • Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis. 2009a;17:553–570. [PMC free article] [PubMed]
  • Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfiled DA, Banks WA. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun. 2009b;23:507–517. [PMC free article] [PubMed]
  • Jen A, Parkyn CJ, Mootoosamy RC, Ford MJ, Warley A, Liu Q, Bu G, Baskakov IV, Moestrup S, McGuinness L, Emptage N, Morris RJ. Neuronal low-density lipoprotein receptor-related protein 1 binds and endocytoses prion fibrils via receptor cluster 4. J Cell Sci. 2010;123:246–255. [PubMed]
  • Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627–1631. [PubMed]
  • Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000;106:1159–1166. [PMC free article] [PubMed]
  • Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997;49:56–61. [PubMed]
  • Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1–12. [PubMed]
  • Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001;56:1683–1689. [PubMed]
  • Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr. 2010;103:730–734. [PubMed]
  • Krikorian R, Shidler MD, Nash TA, Kalt W, Vinqvist-Tymchuk MR, Shukitt-Hale B, Joseph JA. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010;58:3996–4000. [PMC free article] [PubMed]
  • Kounnas MZ, Church FC, Argraves WS, Strickland DK. Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem. 1996;271:6523–6529. [PubMed]
  • Lakshmana MK, Chen E, Yoon IS, Kang DE. C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. J Cell Mol Med. 2008;12:2665–2674. [PMC free article] [PubMed]
  • Lambert JC, Wavrant-De Vrieze F, Amouyel P, Chartier-Harlin MC. Association at LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet. 1998;351:1787–1788. [PubMed]
  • Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094–1099. [PubMed]
  • Latimer CS, Searcy JL, Bridges MT, Brewer LD, Popovic J, Blalock EM, Landfield PW, Thibault O, Porter NM. Reversal of glial and neurovascular markers of unhealthy brain aging by exercise in middle-aged female mice. PLoS One. 2011;6:e26812. [PMC free article] [PubMed]
  • Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135. [PubMed]
  • Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701–713. [PubMed]
  • Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med. 2004;6:663–672. [PubMed]
  • Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, van Mourik JA, Mertens K, van Zonneveld AJ. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274:23734–23739. [PubMed]
  • Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J Biol Chem. 2001;276:18000–18006. [PubMed]
  • Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88:887–918. [PMC free article] [PubMed]
  • Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci. 2005;25:9321–9327. [PubMed]
  • Liu Q, Zhang J, Tran H, Verbeek MM, Reiss K, Estus S, Bu G. LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener. 2009;4:17. [PMC free article] [PubMed]
  • Liu P, Kemper LJ, Wang J, Zahs KR, Ashe KH, Pasinetti GM. Grape seed polyphenolic extract specifically decreases abeta*56 in the brains of Tg2576 mice. J Alzheimers Dis. 2011;26:657–666. [PubMed]
  • Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem. 2002;277:15499–15506. [PubMed]
  • Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res. 2007;85:3036–3040. [PubMed]
  • Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B, Zlokovic BV. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol. 2002;38:303–313. [PubMed]
  • Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest. 1998a;102:734–743. [PMC free article] [PubMed]
  • Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem. 1998b;70:210–215. [PubMed]
  • Maekawa H, Tollefsen DM. Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes. J Biol Chem. 1996;271:18604–18609. [PubMed]
  • Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94–98. [PMC free article] [PubMed]
  • Mann GE, Zlokovic BV, Yudilevich DL. Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta. 1985;819:241–248. [PubMed]
  • Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem. 1997;69:1995–2004. [PubMed]
  • Martel CL, Mackic JB, McComb JG, Ghiso J, Zlokovic BV. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neurosci Lett. 1996;206:157–160. [PubMed]
  • Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000;54:1265–1272. [PubMed]
  • Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010;75:764–770. [PubMed]
  • Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774. [PMC free article] [PubMed]
  • May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem. 2002;277:18736–18743. [PubMed]
  • McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009:CD003160. [PubMed]
  • McKhann GM. Changing concepts of Alzheimer disease. JAMA. 2011;305:2458–2459. [PubMed]
  • Meijer AB, Rohlena J, van der Zwaan C, van Zonneveld AJ, Boertjes RC, Lenting PJ, Mertens K. Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII. Biochim Biophys Acta. 2007;1774:714–722. [PubMed]
  • Middleton LE, Mitnitski A, Fallah N, Kirkland SA, Rockwood K. Changes in cognition and mortality in relation to exercise in late life: a population based study. PLoS One. 2008;3:e3124. [PMC free article] [PubMed]
  • Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 2008;1230:273–280. [PMC free article] [PubMed]
  • Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269:375–382. [PubMed]
  • Moir RD, Tanzi RE. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res. 2005;2:269–273. [PubMed]
  • Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 2002;33:620–626. [PubMed]
  • Moon JH, Kang SB, Park JS, Lee BW, Kang ES, Ahn CW, Lee HC, Cha BS. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression. Metabolism. 2011a;60:930–940. [PubMed]
  • Moon JH, Kim HJ, Yang AH, Kim HM, Lee BW, Kang ES, Lee HC, Cha BS. The effect of rosiglitazone on LRP1 expression and amyloid beta uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2011b:1–8. [PubMed]
  • Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287:3230–3237. [PubMed]
  • Mucke L. Neuroscience: Alzheimer's disease. Nature. 2009;461:895–897. [PubMed]
  • Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904–1911. [PubMed]
  • Natunen T, Helisalmi S, Vepsalainen S, Sarajarvi T, Antikainen L, Makinen P, Herukka SK, Koivisto AM, Haapasalo A, Soininen H, Hiltunen M. Genetic Analysis of Genes Involved in Amyloid-beta Degradation and Clearance in Alzheimer's Disease. J Alzheimers Dis. 2012;28:553–559. [PubMed]
  • Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis. 2008;30:94–102. [PMC free article] [PubMed]
  • Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem. 1999;274:31305–31311. [PubMed]
  • Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14–20. [PubMed]
  • Obermoeller-McCormick LM, Li Y, Osaka H, FitzGerald DJ, Schwartz AL, Bu G. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J Cell Sci. 2001;114:899–908. [PubMed]
  • Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J Cell Sci. 2004;117:5071–5078. [PubMed]
  • Papandreou MA, Dimakopoulou A, Linardaki ZI, Cordopatis P, Klimis-Zacas D, Margarity M, Lamari FN. Effect of a polyphenol-rich wild blueberry extract on cognitive performance of mice, brain antioxidant markers and acetylcholinesterase activity. Behav Brain Res. 2009;198:352–358. [PubMed]
  • Parkyn CJ, Vermeulen EG, Mootoosamy RC, Sunyach C, Jacobsen C, Oxvig C, Moestrup S, Liu Q, Bu G, Jen A, Morris RJ. LRP1 controls biosynthetic and endocytic trafficking of neuronal prion protein. J Cell Sci. 2008;121:773–783. [PubMed]
  • Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS. 2011;8:21. [PMC free article] [PubMed]
  • Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM, Sloan R, Gage FH, Brown TR, Small SA. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci U S A. 2007;104:5638–5643. [PubMed]
  • Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med. 2005;352:2379–2388. [PubMed]
  • Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci. 2004;24:4259–4265. [PubMed]
  • Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Neurobiol Dis. 1997;4:27–34. [PubMed]
  • Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D, Yepes M. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood. 2007;109:3270–3278. [PubMed]
  • Poller W, Willnow TE, Hilpert J, Herz J. Differential recognition of alpha 1-antitrypsin-elastase and alpha 1-antichymotrypsin-cathepsin G complexes by the low density lipoprotein receptor-related protein. J Biol Chem. 1995;270:2841–2845. [PubMed]
  • Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M., Jr Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol. 2002;76:12900–12907. [PMC free article] [PubMed]
  • Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, Chartier-Harlin MC, Hayes A, Thaker U, Iwatsubo T, Mann DM, Lendon C. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett. 2005;382:221–226. [PubMed]
  • Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. 1999;73:1393–1398. [PubMed]
  • Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. J Neuropathol Exp Neurol. 2001;60:430–440. [PubMed]
  • Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem. 1997;272:23946–23951. [PubMed]
  • Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA. Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). Exp Cell Res. 1999;251:433–441. [PubMed]
  • Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62:1047–1051. [PubMed]
  • Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211–217. [PubMed]
  • Rosenberg RN. Treat Alzheimer disease before it is symptomatic. Arch Neurol. 2011;68:1237–1238. [PubMed]
  • Rudling M, Angelin B, Stahle L, Reihner E, Sahlin S, Olivecrona H, Bjorkhem I, Einarsson C. Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver. J Clin Endocrinol Metab. 2002;87:4307–4313. [PubMed]
  • Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13:1029–1031. [PMC free article] [PubMed]
  • Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis. 2011a;24:25–34. [PubMed]
  • Sagare AP, Winkler EA, Bell RD, Deane R, Zlokovic BV. From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid-beta levels. J Neurosci Res. 2011b;89:967–968. [PubMed]
  • Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med. 2012 doi: 10.1101/cshperspect.a006379. [PMC free article] [PubMed]
  • Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl J Med. 1997;336:1216–1222. [PubMed]
  • Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, Souza DO, Figueiredo CP, Farina M. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp Neurol. 2012;233:767–775. [PubMed]
  • Schneider A, Simons M. Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins. J Neurochem. 2012;120:1–3. [PubMed]
  • Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A. 2012 [PubMed]
  • Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001a;81:741–766. [PubMed]
  • Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron. 2001b;32:177–180. [PubMed]
  • Selvais C, D'Auria L, Tyteca D, Perrot G, Lemoine P, Troeberg L, Dedieu S, Noel A, Nagase H, Henriet P, Courtoy PJ, Marbaix E, Emonard H. Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J. 2011;25:2770–2781. [PubMed]
  • Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–1499. [PMC free article] [PubMed]
  • Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, Hosoya K, Terasaki T. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004;24:9632–9637. [PubMed]
  • Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, Yamashita T, Uchiyama Y, Rakugi H, Morishita R. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J Biol Chem. 2010;285:22091–22102. [PubMed]
  • Shukitt-Hale B, Cheng V, Joseph JA. Effects of blackberries on motor and cognitive function in aged rats. Nutr Neurosci. 2009;12:135–140. [PubMed]
  • Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23:307–318. [PubMed]
  • Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol. 2010a;69:1034–1043. [PubMed]
  • Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, Stopa EG, Johanson CE. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol. 2010b;69:98–108. [PubMed]
  • Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88:10540–10543. [PubMed]
  • Stachler MD, Bartlett JS. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 2006;13:926–931. [PubMed]
  • Su HP, Nakada-Tsukui K, Tosello-Trampont AC, Li Y, Bu G, Henson PM, Ravichandran KS. Interaction of CED-6/GULP, an adapter protein involved in engulfment of apoptotic cells with CED-1 and CD91/low density lipoprotein receptor-related protein (LRP). J Biol Chem. 2002;277:11772–11779. [PubMed]
  • Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004;18:323–325. [PubMed]
  • Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res. 2011;89:808–814. [PubMed]
  • Swain RA, Harris AB, Wiener EC, Dutka MV, Morris HD, Theien BE, Konda S, Engberg K, Lauterbur PC, Greenough WT. Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. Neuroscience. 2003;117:1037–1046. [PubMed]
  • Takayama Y, May P, Anderson RG, Herz J. Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). J Biol Chem. 2005;280:18504–18510. [PubMed]
  • Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, Terasaki T. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res. 2006;23:1407–1416. [PubMed]
  • Tamaki C, Ohtsuki S, Terasaki T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol. 2007;72:850–855. [PubMed]
  • Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's A beta peptide: The many roads to perdition. Neuron. 2004;43:605–608. [PubMed]
  • Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556–33560. [PubMed]
  • Tseng CN, Gau BS, Lou MF. The effectiveness of exercise on improving cognitive function in older people: a systematic review. J Nurs Res. 2011;19:119–131. [PubMed]
  • Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. 2003;10:463–470. [PubMed]
  • Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des. 2011;17:2575–2591. [PubMed]
  • van der Geer P. Phosphorylation of LRP1: regulation of transport and signal transduction. Trends Cardiovasc Med. 2002;12:160–165. [PubMed]
  • von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280:17777–17785. [PubMed]
  • Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord. 2006;22:392–398. [PubMed]
  • Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K, Pietrzik CU. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol Dis. 2008;31:188–197. [PubMed]
  • Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006;20:2313–2320. [PubMed]
  • Wang L, Bell P, Lin J, Calcedo R, Tarantal AF, Wilson JM. AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). Mol Ther. 2011;19:2012–2020. [PubMed]
  • Wavrant-DeVrieze F, Lambert JC, Stas L, Crook R, Cottel D, Pasquier F, Frigard B, Lambrechts M, Thiry E, Amouyel P, Tur JP, Chartier-Harlin MC, Hardy J, Van Leuven F. Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. Hum Genet. 1999;104:432–434. [PubMed]
  • White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109:513–519. [PubMed]
  • Williams RJ, Spencer JP. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med. 2012;52:35–45. [PubMed]
  • Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995;92:4537–4541. [PubMed]
  • Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994;264:1471–1474. [PubMed]
  • Wolozin B. Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimers Res Ther. 2012;4:3. [PMC free article] [PubMed]
  • Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439–1443. [PubMed]
  • Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20. [PMC free article] [PubMed]
  • Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, Liu D, Li F, Armstrong D, Gasiewicz T, Zidovetzki R, Song X, Hofman F, Zlokovic BV. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med. 2005;11:959–965. [PubMed]
  • Yamada K, Hashimoto T, Yabuki C, Nagae Y, Tachikawa M, Strickland DK, Liu Q, Bu G, Basak JM, Holtzman DM, Ohtsuki S, Terasaki T, Iwatsubo T. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem. 2008;283:34554–34562. [PubMed]
  • Yamamoto A. A uniqe antilipidemic drug--probucol. J Atheroscler Thromb. 2008;15:304–305. [PubMed]
  • Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685–691. [PubMed]
  • Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004;61:82–88. [PubMed]
  • Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217–224. [PubMed]
  • Zerbinatti CV, Bu G. LRP and Alzheimer's disease. Rev Neurosci. 2005;16:123–135. [PubMed]
  • Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM, Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A. 2004;101:1075–1080. [PubMed]
  • Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging. 2007;28:977–986. [PubMed]
  • Zlokovic BV. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996;59:1483–1497. [PubMed]
  • Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from concept to reality--part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery. 1997;40:789–803. [PubMed]
  • Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202–208. [PubMed]
  • Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723–738. [PubMed]
  • Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from concept to reality-part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery. 1997;40:789–803. [PubMed]
  • Zlokovic BV, Srivastava A, Bell RD, Sagare A, Larson A, Van Nostrand WE, Singh I, Deane R. LRP-1-cluster IV with an improved Alzheimer's Aβ binding specific activity exerts an enhanced Aβ sink action in mice.. Program No.236.10/F10. 2009 Neuroscience Meeting Planner; Chicago, IL: Society for Neuroscience. 2009. Online.
  • Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J Neurochem. 2010;115:1077–1089. [PMC free article] [PubMed]
  • Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 2005;15:78–83. [PubMed]
  • Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun. 1993;197:1034–1040. [PubMed]
  • Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996;93:4229–4234. [PubMed]
  • Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L. Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Res. 1985;358:191–199. [PubMed]
  • Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med. 2000;6:718–719. [PubMed]
  • Zurhove K, Nakajima C, Herz J, Bock HH, May P. Gamma-secretase limits the inflammatory response through the processing of LRP1. Sci Signal. 2008;1:ra15. [PMC free article] [PubMed]